Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daridorexant Phase 3 in Chinese Insomnia Patients
NCT06010693Phase 3Completed
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Aug 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in insomnia disorder comparing Daridorexant 50 mg with Placebo (2 arms). Primary endpoint: Wake After Sleep Onset at Month 1. Started Aug 2023; status: completed.
02
Drugs
daridorexant
03
Conditions
insomnia disorder
Beyond the preview
Go deeper on NCT06010693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06010693.